Ovarian Cancer Market
Key Highlights
- The rate of new cases of ovarian cancer was 10.6 per 100,000 women per year. The death rate was 6.5 per 100,000 women per year. These rates are age-adjusted and based on 2013–2017 cases and 2015–2019 deaths.
- Approximately 1.1 percent of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2017–2019 data.
- In 2019, there were an estimated 233,565 women living with ovarian cancer in the United States.
- The earlier ovarian cancer is caught, the better chance a person has of surviving five years after being diagnosed. For ovarian cancer, 17% are diagnosed at the local stage. The 5-year relative survival for localized ovarian cancer is 93.1%.
- Ovarian Cancer epidemiology [segmented as Total Incident Cases of Ovarian Cancer, Type-specific Incident Cases of Ovarian Cancer, Subtype-specific Incident Cases of Epithelial Ovarian Cancer, Age-specific Incident Cases of Ovarian Cancer, and Total treated Cases of Ovarian Cancer] in the ovarian cancer market report
Request for unlock CAGR of Ovarian Cancer Market
DelveInsight's "Ovarian Cancer Market Insights, Epidemiology, and Market Forecast — 2032" report delivers an in-depth understanding of the Ovarian Cancer, historical and forecasted epidemiology as well as the Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Ovarian Cancer market report provides current treatment practices, emerging drugs, Ovarian Cancer market share of the individual therapies, current and forecasted Ovarian Cancer market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Ovarian Cancer treatment practice/algorithm, and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Ovarian Cancer Market Disease: Understanding and Treatment Algorithm
The DelveInsight’s Ovarian Cancer market report gives a thorough understanding of Ovarian Cancer by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Ovarian cancer is a disease that affects women and is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.
In its early stages, ovarian cancer usually does not cause noticeable symptoms. As the cancer progresses, signs and symptoms can include pain or a feeling of heaviness in the pelvis or lower abdomen, bloating, feeling full quickly when eating, back pain, vaginal bleeding between menstrual periods or after menopause, or changes in urinary or bowel habits. However, these changes can occur as part of many different conditions. Having one or more of these symptoms does not mean that a woman has ovarian cancer.
Ovarian Cancer Diagnosis
Ovarian cancer is diagnosed using transvaginal ultrasound and a blood test to detect a protein called CA-125. The ultrasound can detect a tumor or mass but cannot tell if the mass is cancerous or benign. CA-125 is measured because it is often found at elevated levels in the bloodstream of people with ovarian cancer. The diagnosis is then confirmed by pathology—laboratory testing of a sample of the tumor cells, usually done after surgery to remove the tumor.
Ovarian Cancer Treatment
Platinum-based chemotherapy (usually in combination with surgery) is the mainstay first line drug treatment for ovarian cancer tumors. Optimal management of advanced ovarian cancer includes histopathological diagnosis, accurate surgical staging, debulking surgery and platinum-based chemotherapy. The combination of carboplatin and paclitaxel is commonly recognized as the standard regimen because of tolerability and activity.
Ovarian Cancer Epidemiology
The Ovarian Cancer epidemiology section provides insights about historical and current Ovarian Cancer patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Ovarian Cancer epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
According to the Surveillance, Epidemiology, and End Results Program, Cancer Stat Facts: Ovary Cancer, 2022:
- The rate of new cases of ovarian cancer was 10.6 per 100,000 women per year. The death rate was 6.5 per 100,000 women per year. These rates are age-adjusted and based on 2013–2017 cases and 2015–2019 deaths.
- Approximately 1.1 percent of women will be diagnosed with ovarian cancer at some point during their lifetime, based on 2017–2019 data.
- In 2019, there were an estimated 233,565 women living with ovarian cancer in the United States.
- The earlier ovarian cancer is caught, the better chance a person has of surviving five years after being diagnosed. For ovarian cancer, 17% are diagnosed at the local stage. The 5-year relative survival for localized ovarian cancer is 93.1%.
- The disease epidemiology covered in the report provides historical as well as forecasted Ovarian Cancer epidemiology [segmented as Total Incident Cases of Ovarian Cancer, Type-specific Incident Cases of Ovarian Cancer, Subtype-specific Incident Cases of Epithelial Ovarian Cancer, Age-specific Incident Cases of Ovarian Cancer, and Total treated Cases of Ovarian Cancer] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Ovarian Cancer Epidemiology
This section provides glimpse of the Ovarian Cancer epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
Learn more about the evolving epidemiology trends and key developments: Ovarian Cancer Epidemiology Forecast
Ovarian Cancer Drug Chapters
The drug chapter segment of the Ovarian Cancer report encloses the detailed analysis of Ovarian Cancer marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Ovarian Cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Ovarian Cancer Marketed Drugs
LYNPARZA (olaparib): AstraZeneca and MSD's
LYNPARZA (olaparib) is a first-in-class oral poly ADP ribose polymerase (PARP) inhibitor indicated for the treatment of ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. LYNPARZA targets PARP to disrupt the DNA-repair process and potentially kill tumor cells
Note: Detailed Current therapies assessment will be provided in the full report of Ovarian Cancer
Ovarian Cancer Emerging Drugs
AVB-500 (Batiraxcept) is a therapeutic recombinant fusion protein that is being developed by Aravive Biologics and has shown to neutralize GAS6 activity by binding to GAS6 with very high affinity in preclinical models. The drug selectively inhibits the GAS6-AXL signaling pathway, which is upregulated in multiple cancer types, including ovarian cancer. In preclinical studies, GAS6-AXL inhibition has shown antitumor activity in combination with a variety of anticancer therapies, including radiation therapy, immuno-oncology agents, and chemotherapeutic drugs that affect DNA replication and repair. AVB-500 has been granted Fast Track Designation by the US FDA and currently it is being studied in Phase III trial.
Mirvetuximab soravtansine which is being developed by Immunogen is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. It is being studied in later line platinum-sensitive ovarian cancer and in combination in both platinum-resistant and platinum-sensitive diseases. The US FDA and EMA granted orphan drug designation to Mirvetuximab for the treatment of ovarian cancer. Furthermore, FDA granted Mirvetuximab Fast Track designation for the treatment of patients with medium to high FRα-positive platinum-resistant ovarian cancer who received at least one, but no more than three prior systemic treatment regimens, and for whom single-agent chemotherapy is appropriate as the next line of therapy. Currently, the drug is being studied in Phase III trial.
Note: Detailed emerging therapies assessment will be provided in the full report of Ovarian Cancer
Ovarian Cancer Market Outlook
The treatment goal of ovarian cancer usually is to kill the cancer cells or remove the tumor so that the cancerous cells don’t metastasize and to prevent the recurrence of cancer and slow down growth. Sometimes the aim is to treat the symptoms in case of incurable cases by using chemotherapy, radiation, hormonal therapies, targeted drugs or a combination of any of these as per the requirement. In case of early-stage ovarian cancer, surgery is performed to remove the tumor and stage cancer followed by chemotherapy to prevent recurrence of ovarian cancer or to shrink the tumor if the tumor could not be removed by surgery. The aim is to increase the survival rate. In advanced stages of cancer (Stage III and IV) the focus is to put the tumor into remission so that it shrinks or disappears. In the case of cancer relapse, Chemotherapy is again used as a treatment option.
At present, Avastin (bevacizumab; Genentech), Zejula (niraparib; GlaxoSmithKline), Rubraca (rucaparib; Clovis Oncology), Lynparza (AstraZeneca), are a few approved drug therapies for the treatment of Ovarian Cancer. Rubraca (Clovis Oncology), Zejula (niraparib; GlaxoSmithKline), and Lynparza (olaparib; AstraZeneca), are a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.
There are a number of treatments that can be effective in Ovarian Cancer, but still, there are many unmet needs need in terms of both efficacy and safety, with a cure for the disease being the most important unmet need in the market. Ovarian cancer treatment currently consists mainly of surgery and chemotherapy; however, under these regimens, many patients suffer a relapse or develop recurrent tumors that are resistant or refractory to further therapy. The inability of current market offerings to alter the natural course of the disease and improve patients’ quality of life indicates that there is an unmet need for drugs with better efficacy profiles. The percentage of ovarian cancer patients who suffer adverse effects from drug treatments is high, and these patients could benefit from newer, next-generation products.
To redress the existing issues, currently, there are many possible new treatment options emerging from recent ovarian cancer clinical trial, based both on the modifications of standard approaches and on the addition of new biological drugs to the standard treatment.
The emerging drugs for ovarian cancer shall impact the market size significantly, considering the pipeline with a variety of therapeutic classes in the periphery. At present there are decent number of biologics and drugs under investigation for the treatment of ovarian cancer. Key players such as Immunogen, Aravive Biologics, Mersana Therapeutics, Alkermes are some of the major players that are going to boost the market dynamics in the coming years.
According to DelveInsight, Ovarian Cancer market in 7MM is expected to witness a change in the study period 2019-2032.
Analyst Commentary
- The pipeline of Ovarian Cancer has many potential therapies are being investigated for the treatment of Ovarian Cancer, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.
- The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Ovarian Cancer market in the 7MM. Aside from that, the market size of Ovarian Cancer may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.
- The market growth of Ovarian Cancer may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2032 |
|
CAGR |
|
|
Ovarian Cancer Drugs |
Tisotumab Vedotin, Pembrolizumab, Adavosertib, AVB-500, and others. |
|
Ovarian Cancer Key Companies |
Genmab, AstraZeneca, On Target Laboratories, Chipscreen Biosciences, Aravive, Inc., Allarity Therapeutics, Merck KGaA, GlaxoSmithKline, Aprea Therapeutics, Verastem, Inc., Ellipses Pharma, Impact Therapeutics, Inc., BeiGene, Apexigen, Novartis Oncology, VBL Therapeutics., Cristal Therapeutics, Bayer, Regeneron Pharmaceuticals, DCPrime BV, AIM ImmunoTech Inc., Pharmicell Co., Ltd., Shattuck Labs, Inc., Laekna Limited, Celsion, and Many Others. |
Ovarian Cancer Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the Ovarian Cancer market or expected to get launched in the market during the study period 2019-2032. The analysis covers Ovarian Cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Note: Detailed emerging therapies assessment will be provided in full report of Ovarian Cancer
Ovarian Cancer Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyses Ovarian Cancer key players involved in developing targeted therapeutics.
Ovarian Cancer Clinical Trial Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Ovarian Cancer emerging therapies.
Learn more about the emerging therapies and key companies active in the therapeutics segment: Ovarian Cancer Pipeline Insight
Reimbursement Scenario in Ovarian Cancer
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Ovarian Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Ovarian Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitive and Market Intelligence analysis of the Ovarian Cancer Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Ovarian Cancer Market Report
- The report covers the descriptive overview of Ovarian Cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Ovarian Cancer epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Ovarian Cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Ovarian Cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- Detailed Patient Based Market Forecasting determines the trends shaping and driving the Global Ovarian Cancer market
Ovarian Cancer Market Report Highlights
- In the coming years, the Ovarian Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Ovarian Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Ovarian Cancer. The launch of emerging therapies will significantly impact the Ovarian Cancer market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Ovarian Cancer
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Ovarian Cancer Report Insights
- Patient Based Market Forecasting
- Therapeutic Approaches
- Ovarian Cancer Pipeline Analysis
- Ovarian Cancer Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Ovarian Cancer Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Ovarian Cancer Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Ovarian Cancer Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
Key Questions
Market Insights:
- What was the Ovarian Cancer drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Ovarian Cancer total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings of the market across 7MM and which country will have the largest Ovarian Cancer market size during the forecast period (2019-2032)?
- At what CAGR, the Ovarian Cancer market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Ovarian Cancer market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Ovarian Cancer market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Ovarian Cancer?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Ovarian Cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Ovarian Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Ovarian Cancer?
- Out of all 7MM countries, which country would have the highest incident population of Ovarian Cancer during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Ovarian Cancer treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Ovarian Cancer in the USA, Europe, and Japan?
- What are the Ovarian Cancer marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Ovarian Cancer?
- How many therapies are in-development by each company for Ovarian Cancer treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Ovarian Cancer treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ovarian Cancer therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Ovarian Cancer and its status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies Ovarian Cancer?
- What are the global historical and forecasted markets of Ovarian Cancer?
Reasons to buy
- The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Ovarian Cancer market
- Organize sales and marketing efforts by identifying the best opportunities for Ovarian Cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Ovarian Cancer market
- To understand the future market competition in the Ovarian Cancer market
Frequently Asked Questions
1 Key Insights
2 Report Introduction
3 Ovarian Cancer Market Overview at a Glance
3.1 Drug-class Share (%) Distribution of Ovarian Cancer in 2019
3.2 Drug-class Share (%) Distribution of Ovarian Cancer in 2032
4 Executive Summary of Ovarian Cancer
4.1 Key Events
5 Epidemiology and Market Methodology
6 Disease Background and Overview
6.1 Introduction
6.2 Classification of Ovarian Cancer
6.4 Signs and Symptoms
6.5 Causes and Risk Factors
6.6 Pathophysiology
6.7 Genetic Findings in Ovarian Cancer
6.8 Biomarkers
7 Diagnosis of Ovarian Cancer
7.1 Diagnostic Algorithm
7.2 Diagnostic Guidelines
8 Current Treatment Practices of Ovarian Cancer
8.1 Treatment of Ovarian Cancer
8.1.1 Treatment Algorithm
8.2 Treatment Guidelines
9 Epidemiology and Patient Population
9.1 Key Findings
9.2 Assumption and Rationale
9.3 Epidemiology Scenario in the 7MM
9.3.1 Total Incident Cases of Ovarian Cancer in the 7MM (2019-2032)
9.3.2 Type-specific Incident cases of Ovarian Cancer (2019–2032)
9.3.3 Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the 7MM (2019-2032)
9.3.4 Age-specific Incident Cases of Ovarian Cancer in the 7MM (2019–2032)
9.3.5 Total Treated Cases of Ovarian Cancer by line of therapies in the 7MM (2019–2032)
9.4 Epidemiology Scenario in the United States
9.4.1 Total Incident Cases of Ovarian Cancer in the United States (2019-2032)
9.4.2 Type-specific Incident cases of Ovarian Cancer in the United States (2019–2032)
9.4.3 Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the United States (2019-2032)
9.4.4 Age-specific Incident Cases of Ovarian Cancer in the United States (2019–2032)
9.4.5 Total Treated Cases of Ovarian Cancer by line of therapies in the United States (2019–2032)
9.5 Epidemiology Scenario in the EU-5
9.5.1 Total Incident Cases of Ovarian Cancer in the EU-5 (2019-2032)
9.5.2 Type-specific Incident cases of Ovarian Cancer in the EU-5 (2019–2032)
9.5.3 Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the EU-5 (2019-2032)
9.5.4 Age-specific Incident Cases of Ovarian Cancer in the EU-5 (2019–2032)
9.5.5 Total Treated Cases of Ovarian Cancer by line of therapies in the EU-5 (2019–2032)
9.6 Epidemiology Scenario in Japan
9.6.1 Total Incident Cases of Ovarian Cancer in Japan (2019-2032)
9.6.2 Type-specific Incident cases of Ovarian Cancer in Japan (2019–2032)
9.6.3 Subtype-specific Incident Cases of Epithelial Ovarian Cancer in Japan (2019-2032)
9.6.4 Age-specific Incident Cases of Ovarian Cancer in Japan (2019–2032)
9.6.5 Total Treated Cases of Ovarian Cancer by line of therapies in Japan (2019–2032)
10 Patient Journey
11 Key Endpoints in Ovarian Cancer Clinical Trials
12 Marketed Therapies
12.1 Zejula (Niraparib): GlaxoSmithKline
12.1.1 Drug Description
12.1.2 Regulatory Milestones
12.1.3 Other Developmental Activities
12.1.4 Pivotal Clinical Trial
12.1.5 Ongoing Current Pipeline Activity
To be continued in the report
13 Emerging Therapies
13.1 Mirvetuximab soravtansine; ImmunoGen
13.1.1 Product Description
13.1.2 Other developmental activities
13.1.3 Clinical Development
13.1.4 Safety and Efficacy
13.2 AVB-500: Aravive Biologics
13.2.1 Product Description
13.2.2 Other Developmental Activities
13.2.3 Clinical Development
13.2.4 Safety and Efficacy
13.3 Upifitamab Rilsodotin : Mersana Therapeutics
13.3.1 Product Description
13.3.2 Other Developmental Activities
13.3.3 Clinical Development
13.3.4 Safety and Efficacy
To be continued in the report
14 Conjoint Analysis
15 Ovarian Cancer : 7 Major Market Analysis
15.1 Key Findings
15.2 Market Outlook
15.3 Market Size of Ovarian Cancer in the 7MM
15.3.1 Total Market Size of Ovarian Cancer in the 7MM
15.3.2 Market Size by Therapies for Early stage disease in the 7MM
15.3.3 Market Size by Therapies in First Line Ovarian Cancer Cases in the 7MM
15.3.4 Market Size by Therapies in Second Line Ovarian Cancer Cases in the 7MM
15.3.5 Market Size by Therapies in Third Line Ovarian Cancer Cases in the 7MM
15.3.6 Market Size by Therapies in Fourth Line and above Ovarian Cancer Cases in the 7MM
15.4 Market Size of Ovarian Cancer in the United States
15.4.1 Total Market Size of Ovarian Cancer in the United States
15.4.2 Market Size by Therapies for Early stage disease in the United States
15.4.3 Market Size by Therapies in First Line Ovarian Cancer Cases in the United States
15.4.4 Market Size by Therapies in Second Line Ovarian Cancer Cases in the United States
15.4.5 Market Size by Therapies in Third Line Ovarian Cancer Cases in the United States
15.4.6 Market Size by Therapies in Fourth Line and above Ovarian Cancer Cases in the United States
15.5 Market Size of Ovarian Cancer in EU-5
15.5.1 Total Market Size of Ovarian Cancer in EU-5
15.5.2 Market Size by Therapies for Early stage disease in EU-5
15.5.3 Market Size by Therapies in First Line Ovarian Cancer Cases in EU-5
15.5.4 Market Size by Therapies in Second Line Ovarian Cancer Cases in EU-5
15.5.5 Market Size by Therapies in Third Line Ovarian Cancer Cases in EU-5
15.5.6 Market Size by Therapies in Fourth Line and above Ovarian Cancer Cases in EU-5
15.6 Market Size of Ovarian Cancer in Japan
15.6.1 Total Market Size of Ovarian Cancer in Japan
15.6.2 Market Size by Therapies for Early stage disease in Japan
15.6.3 Market Size by Therapies in First Line Ovarian Cancer Cases in Japan
15.6.4 Market Size by Therapies in Second Line Ovarian Cancer Cases in Japan
15.6.5 Market Size by Therapies in Third Line Ovarian Cancer Cases in Japan
15.6.6 Market Size by Therapies in Fourth Line and above Ovarian Cancer Cases in Japan
16 Market Access and Reimbursement
16.1 Reimbursement
16.2 Key HTA decisions
16.3 Patient Access Programs
17 KOL Views
18 SWOT Analysis
19 Unmet Needs
20 Appendix
20.1 Bibliography
20.2 Report Methodology
21 DelveInsight Capabilities
22 Disclaimer
23 About DelveInsight
Table 1: Total Incident Cases of Ovarian Cancer in the 7MM
Table 2: Type-specific Incident cases of Ovarian Cancer in the 7MM(2019–2032)
Table 3: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the 7MM (2019-2032)
Table 4: Age-specific Incident Cases of Ovarian Cancer in the 7MM [2019–2032]
Table 5: Total Treated Cases of Ovarian Cancer in the 7MM [2019–2032]
Table 6: Total Incident Cases of Ovarian Cancer in the United States (2019-2032)
Table 7: Type-specific Incident cases of Ovarian Cancer in the United States (2019–2032)
Table 8: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the United States (2019-2032)
Table 9: Age-specific Incident Cases of Ovarian Cancer in the United States [2019–2032]
Table 10: Total Treated Cases of Ovarian Cancer in the United States [2019–2032]
Table 11: Total Incident Cases of Ovarian Cancer in the EU-5 (2019-2032)
Table 12: Type-specific Incident cases of Ovarian Cancer in the EU-5 (2019–2032)
Table 13: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the EU-5 (2019-2032)
Table 14: Age-specific Incident Cases of Ovarian Cancer in the EU-5 [2019–2032]
Table 15: Total Treated Cases of Ovarian Cancer in the EU-5 [2019–2032]
Table 16: Total Incident Cases of Ovarian Cancer in Japan (2019–2032)
Table 17: Type-specific Incident cases of Ovarian Cancer in Japan (2019–2032)
Table 18: Grade-specific Incident cases of Ovarian Cancer in Japan (2019–2032)
Table 19: Age-specific Incident Cases of Ovarian Cancer in Japan [2019–2032]
Table 20: Total Treated Cases of Ovarian Cancer in Japan (2019–2032)
Table 21: AVB-500, Clinical Trials by Recruitment status, 2021
Table 22: AVB-500, Clinical Trials by Zone, 2021
Table 23: Total Seven Major Market Size in USD, Million (2019–2032)
Table 24: 7MM-Market Size by Therapies in USD, Million (2019–2032)
Table 25: United States Market Size in USD, Million (2019–2032)
Table 26: United States Market Size by Therapies in USD, Million (2019–2032)
Table 27: EU-5 Market Size in USD, Million (2019-2032)
Table 28: EU-5 Market Size by Therapies in USD, Million (2019–2032)
Table 29: Japan Market Size in USD, Million (2019–2032)
Table 30: Japan Market Size by Therapies in USD, Million (2019–2032)
List of Figures
Figure 1: Total Incident Cases of Ovarian Cancer in the 7MM
Figure 2: Type-specific Incident cases of Ovarian Cancer in the 7MM(2019–2032)
Figure 3: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the 7MM (2019-2032)
Figure 4: Age-specific Incident Cases of Ovarian Cancer in the 7MM [2019–2032]
Figure 5: Total Treated Cases of Ovarian Cancer in the 7MM [2019–2032]
Figure 6: Total Incident Cases of Ovarian Cancer in the United States (2019-2032)
Figure 7: Type-specific Incident cases of Ovarian Cancer in the United States (2019–2032)
Figure 8: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the United States (2019-2032)
Figure 9: Age-specific Incident Cases of Ovarian Cancer in the United States [2019–2032]
Figure 10: Total Treated Cases of Ovarian Cancer in the United States [2019–2032]
Figure 11: Total Incident Cases of Ovarian Cancer in the EU-5 (2019-2032)
Figure 12: Type-specific Incident cases of Ovarian Cancer in the EU-5 (2019–2032)
Figure 13: Subtype-specific Incident Cases of Epithelial Ovarian Cancer in the EU-5 (2019-2032)
Figure 14: Age-specific Incident Cases of Ovarian Cancer in the EU-5 [2019–2032]
Figure 15: Total Treated Cases of Ovarian Cancer in the EU-5 [2019–2032]
Figure 16: Total Incident Cases of Ovarian Cancer in Japan (2019–2032)
Figure 17: Type-specific Incident cases of Ovarian Cancer in Japan (2019–2032)
Figure 18: Grade-specific Incident cases of Ovarian Cancer in Japan (2019–2032)
Figure 19: Age-specific Incident Cases of Ovarian Cancer in Japan [2019–2032]
Figure 20: Total Treated Cases of Ovarian Cancer in Japan (2019–2032)
Figure 21: Total Seven Major Market Size in USD, Million (2019–2032)
Figure 22: 7MM-Market Size by Therapies in USD, Million (2019–2032)
Figure 23: United States Market Size in USD, Million (2019–2032)
Figure 24: United States Market Size by Therapies in USD, Million (2019–2032)
Figure 25: EU-5 Market Size in USD, Million (2019-2032)
Figure 26: EU-5 Market Size by Therapies in USD, Million (2019–2032)
Figure 27: Japan Market Size in USD, Million (2019–2032)
Figure 28: Japan Market Size by Therapies in USD, Million (2019–2032)